IBL HealthCare Limited has transmitted its audited financial statements for the year ended June 30, 2026, highlighting a steady growth in revenue and profit amid challenging economic conditions.
- Revenue increased by 7% to PKR 4,607M (FY25: PKR 4,322M)
- Gross profit rose 14% to PKR 1,645M, with a gross margin of 35.7% (FY25: 33.5%)
- Profit after tax (PAT) grew 6% to PKR 220M (FY25: PKR 208M)
- Earnings per share (EPS) increased to PKR 2.24 (FY25 restated: PKR 2.11)
- Operating expenses rose by 21%, influenced by inflation and increased marketing efforts
- Finance costs decreased by 29% to PKR 43M (FY25: PKR 60M)
- Cash and bank balances improved significantly from PKR 209M to PKR 727M
The report reflects a cautious optimism as the company navigates through external economic pressures while maintaining operational efficiency.